Restore Prescription Drugs Discount Act
- Sponsor
- Sen. Paul, Rand [R-KY]
- Committees
- Judiciary Committee (primary)
- Last action
- Jun 17, 2025
Bottom line
The bill aims to remove a Depression-era antitrust law that prohibits price discrimination, with proponents arguing it would foster greater competition and lower prices, while opponents fear it could harm small businesses and lead to predatory pricing.
What it actually does
This bill proposes to fully repeal the Act of June 19, 1936, commonly known as the Robinson-Patman Act, and all amendments made by that Act. The Robinson-Patman Act is a federal law that prohibits price discrimination, where a seller charges different prices to different buyers for the same goods, particularly if it substantially lessens competition or tends to create a monopoly. Its repeal would eliminate these specific prohibitions.
Proponents argue
Supporters argue that the Robinson-Patman Act is an outdated and anti-competitive law that stifles efficient pricing, innovation, and consumer welfare. They contend that its repeal would allow for more dynamic pricing strategies, encourage competition among suppliers, and ultimately lead to lower prices for consumers, particularly in the prescription drug market as suggested by the bill's short title.
Opponents contend
Opponents contend that repealing the Robinson-Patman Act would remove crucial protections for small businesses against the market power of large retailers and manufacturers. They argue it could enable predatory pricing practices, where large corporations could demand preferential pricing, driving smaller competitors out of business and ultimately leading to less competition and potentially higher prices for consumers in the long run.
The bill text is exceptionally short and clear, allowing for rapid understanding of its direct legislative action.
Section 2
Repeal of the Robinson-Patman Act of 1936
This section explicitly repeals the Robinson-Patman Act of 1936, which is codified at 15 U.S.C. 13a et seq. The Robinson-Patman Act generally prohibits sellers from discriminating in price between different purchasers of commodities of like grade and quality, where the effect of such discrimination may be to substantially lessen competition or tend to create a monopoly. Its repeal would remove these specific prohibitions from federal law.
Supporters argue
Supporters argue that repealing this provision would remove an outdated barrier to free market competition, allowing businesses to set prices more efficiently and respond to market demands. They believe it would particularly benefit consumers by fostering competition that drives down prices, especially for essential goods like prescription drugs.
Critics contend
Critics contend that repealing this provision would eliminate a vital safeguard for fair competition, enabling large corporations to engage in predatory pricing and squeeze out smaller businesses. They argue that this could lead to increased market concentration, reduced choice for consumers, and ultimately higher prices once competition is diminished.
Tradeoffs
This provision navigates the tension between promoting unfettered market competition and protecting smaller market participants from the potentially overwhelming power of larger entities. It balances the desire for pricing efficiency against concerns about market fairness and the prevention of monopolies.